Nov 19, 2021
HIV Therapeutics Market is expected to evolve owing to the launch of novel therapies and the active participation of pharma companies...
Read More...
Nov 05, 2021
IgA Nephropathy Treatment Market is evolving with the active participation of the key companies developing therapies and the rising incidence
Read More...
Nov 03, 2021
Key factors such as advancement in technology, rising awareness, and keen interest by leading companies in the
Read More...
Nov 01, 2021
In the first half of 2021, leading pharma companies have launched more than 12+ therapies, which includes Evkeeza, Lybalvi, Abecma, Lupykynis,
Read More...
Oct 29, 2021
HIV-1 Therapeutics Market is expected to grow with the entry of novel therapies and the R&D activities by key companies including GSK, Merck,
Read More...
Oct 27, 2021
The United States (US) tops the global pharmaceutical industry and accounts for 46% of total global revenue followed by China, Japan, Germany
Read More...
Oct 25, 2021
von Willebrand Disease (vWD) treatment market in the US is categorized as Replacement therapy, Adjunct therapy, and Non-replacement therapy..
Read More...
Oct 22, 2021
Globally, leading companies in the gene therapies for dermatology such as Krystal Biotech, Kastle Creek, Azitra, Abeona, Amryt, Holostem, and
Read More...
Oct 18, 2021
Gene therapy is becoming a pioneer in treating dermatology diseases and pharma companies are actively working on new gene therapies
Read More...
Oct 15, 2021
Heart failure (HF), also referred to as Congestive Heart failure (CHF), is a condition in which the heart muscle fails to pump blood as efficiently as it should. This causes an accumulation of blood and fluid in the lungs, resulting in shortness of breath. Certain heart conditions, such as narrowed arteries in the ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper